



No. 08-039648- -00002-0000

Fecha: 2008-08-12 16:48:57 Dep. 2020 NUECREACION
Tra. 11 PATENTE IYII Eva: 378 FASE NACIONAL I
Act. 444 RESPUESTA REQUE Folios: 34

AS: 106.800

Señora Jefe
DIVISION DE NUEVAS CREACIONES
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
E. S. D.

RESPUESTA A OFICIO 8109 DE 20 JUNIO 2008

REF: Expediente No. 08 039648- Solicitud de Patente Entrada en Fase Nacional
Corresp. a la Solicitud Internacional PCT/US2006/037714
a favor de **CYPRESS BIOSCIENCE, INC.**

Titulada: MILNACIPRAN PARA EL TRATAMIENTO A LARGO PLAZO DEL
SINDROME DE FIBROMIALGIA

JUAN PABLO CADENA SARMIENTO, vecino de Bogotá, portador de la tarjeta profesional No. 57492, obrando como apoderado de la sociedad **CYPRESS BIOSCIENCE, INC.**, según lo acredita el documento de poder anexo al presente escrito, para dar cumplimiento al requerimiento notificado por fijación en lista el 20 de junio de 2008, de acuerdo con los Artículos 38 y 39 de la Decisión 486 de la Comisión de la Comunidad Andina, Artículo 27 del Tratado de Cooperación en Materia de Patentes (PCT), regla 51 bis del Reglamento y Circular Única de la SIC, me permito allegar:

1. Documento donde consta la cesión del derecho a la Patente otorgado por los inventores al solicitante, debidamente apostillado, junto con su correspondiente traducción al castellano.
2. Fotocopia autenticada del documento de poder conferido por el solicitante, incluyendo el Certificado que acredita la Existencia y Representación Legal de **CYPRESS BIOSCIENCE, INC.**, debidamente apostillado y traducido al castellano.
3. Copia Reporte Preliminar Internacional sobre la Patentabilidad; Reportes de Búsqueda Internacional y de la Opinión Escrita efectuada por la Oficina Internacional (Formas PCT/IB/326, PCT/IB/373 y PCT/ISA/237).
4. Extracto para publicación y Tarjeta de Archivo Temático.

De la señora Jefe atentamente,

JUAN PABLO CADENA SARMIENTO
C.C. No. 80.410.337 de Usaquén
Cra. 7 No.71-21, Torre B, Piso 4

Bogotá, 12 de agosto de 2008
MEV/CAG/aac

(21) N° de solicitud: 08 039648

(22) Fecha de solicitud: 18-04-2008

(51) Clasificación Internacional:

(71) Solicitante(s): CYPRESS BIOSCIENCE, INC.

(72) Inventor(es): Srinivas G. RAO, Michael GENDREAU, Jay D. KRANZLER

(74) Agente: JUAN PABLO CADENA SARMIENTO

(30) Prioridad

(31)

No. Prioridad

(32)

Fecha

(33)

País

60/721,722

28-09-2005

US

(85) Fecha inicio fase nacional: 28-04-2008

(86) Datos relativos a la presentación de la solíc. PCT

Fecha de presentación de la solicitud: 27-09-2006

No. de solicitud: PCT/US2006/037714

(87) Publicación internacional:

Fecha: 05-04-2007

No. Publicación: WO 2007/038620 A2

FIGURA CARACTERISTICA

6 x 6 cm

{54} Título: MILNACIPRAN PARA EL TRATAMIENTO A LARGO PLAZO DEL SINDROME DE FIBROMIALGIA

{57} Reivindicación(es):

1. Un método para prever el tratamiento a largo plazo del síndrome de fibromialgia en un paciente que lo requiere por medio de la administración de un inhibidor de absorción dual (DRI) al paciente por lo menos por tres meses.
8. El método de tratamiento de la fibromialgia y sus síntomas en pacientes sufriendo de fibromialgia, el cual comprende: a. administrando aproximadamente 200 mg/día de milnaciprina al paciente para el tratamiento de dolor agudo; b. disminuyendo la dosificación de milnaciprina aproximadamente a 100 mg/día cuando el dolor agudo ha sido tratado; y c. administrando aproximadamente 100 mg/día al paciente por lo menos por tres meses para el tratamiento a largo plazo de la fibromialgia y sus síntomas.

CONTINUA AL RESPALDO ...

2
68

PCTNOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
PRELIMINARY REPORT ON PATENTABILITY
(CHAPTER I OF THE PATENT COOPERATION
TREATY)

(PCT Rule 44bis.1(c))

From the INTERNATIONAL BUREAU

To:

LUDWIG, S., Peter
Darby & Darby P.C.
P.O. Box 770
Church Street Station
New York, NY 10008-0770
ETATS-UNIS D'AMERIQUEDate of mailing (day/month/year)
10 April 2008 (10.04.2008)Applicant's or agent's file reference
2203444-WO0

IMPORTANT NOTICE

International application No.
PCT/US2006/037714International filing date (day/month/year)
27 September 2006 (27.09.2006)Priority date (day/month/year)
28 September 2005 (28.09.2005)

Applicant

CYPRESS BIOSCIENCE, INC. et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Ellen Moyse

Facsimile No. +41 22 338 82 70

e-mail: pt02.pct@wipo.int

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY
(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 2203444-WO0	FOR FURTHER ACTION	See item 4 below
International application No. PCT/US2006/037714	International filing date (day/month/year) 27 September 2006 (27.09.2006)	Priority date (day/month/year) 28 September 2005 (28.09.2005)
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237		
Applicant CYPRESS BIOSCIENCE, INC.		

1. This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).

2. This REPORT consists of a total of 6 sheets, including this cover sheet.

In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.

3. This report contains indications relating to the following items:

- | | |
|---|---|
| ☒ Box No. I | Basis of the report |
| ☐ Box No. II | Priority |
| ☐ Box No. III | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability |
| ☐ Box No. IV | Lack of unity of invention |
| ☒ Box No. V | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| ☐ Box No. VI | Certain documents cited |
| ☒ Box No. VII | Certain defects in the international application |
| ☐ Box No. VIII | Certain observations on the international application |

4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).

Date of issuance of this report
01 April 2008 (01.04.2008)

Authorized officer

Ellen Moyse

e-mail: pf02.pct@wipo.int

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 338 82 70

Form PCT/IB/373 (January 2004)

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

PCT

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

To: S. Peter Ludwig
Darby & Darby PC
P.O. Box 5257
New York, New York 10150-5257

Date of mailing
(day/month/year) **23 AUG 2007**

Applicant's or agent's file reference
2203444-W00

FOR FURTHER ACTION

See paragraph 2 below

International application No.
PCT/US06/37714

International filing date (day/month/year)
27 September 2006 (27.09.2006)

Priority date (day/month/year)
28 September 2005 (28.09.2005)

International Patent Classification (IPC) or both national classification and IPC
IPC(8) - A61K31/165 (2007.01)
USPC - 514/619

Applicant **Cypress Bioscience, Inc.**

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☒ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Date of completion of this opinion
29 April 2007 (29.04.2007)

Authorized officer:
Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

Form PCT/ISA/237 (cover sheet) (April 2005)

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US06/37714

Box No. 1 Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of:

- ☒ the international application in the language in which it was filed
☐ a translation of the international application into _____, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

- ☐ a sequence listing
☐ table(s) related to the sequence listing

b. format of material

- ☐ on paper
☐ in electronic form

c. time of filing/furnishing

- ☐ contained in the international application as filed
☐ filed together with the international application in electronic form
☐ furnished subsequently to this Authority for the purposes of search

3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/US06/37714

874

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-20	YES
	Claims	none	NO
Inventive step (IS)	Claims	none	YES
	Claims	1-20	NO
Industrial applicability (IA)	Claims	1-20	YES
	Claims	none	NO

2. Citations and explanations:

Claims 1-20 lack an inventive step under PCT Article 33(3) as being obvious over US 2004/0228830 A1 to Hirsh et al. (hereinafter "Hirsh").

As per claim 1, 2, and 3, directed to a method of providing long-term treatment of fibromyalgia syndrome, Hirsh discloses that milnacipran which is a norepinephrine (NE) and serotonin (5-HT) reuptake inhibitor (NSRI) (para [0004]) could produce a therapeutic effect over fibromyalgia syndrome patients (para [0017]) and that Patients received either milnacipran 75-100 mg/day twice daily for 8 weeks (para [0007]). It would have been obvious for a person having ordinary skills in the art to administer milnacipran, an NSRI and a dual re-uptake inhibitor (DRI), to provide a long-term treatment for fibromyalgia.

As per claim 4, directed to the method of claims 3, respectively, it is obvious for reasons set forth for claim 3, and further because Hirsh discloses that patients received either milnacipran 75-100 mg/day twice daily (para [0007]). It would have been obvious for a person having ordinary skills in the art to further specify that the milnacipran is administered in a dose between about 25 mg per day and about 400 mg per day.

As per claims 5, 6, directed to the method of claim 4, respectively, they are obvious for reasons set forth for claim 4, and further because Hirsh discloses that in a double-blind, randomized, multicenter clinical study, patients received 100 mg/day milnacipran or 200 mg/day (para [0007]). It would have been obvious for a person having ordinary skills in the art to further specify that the milnacipran is administered in a dose of about 100 mg per day or 200 mg per day.

As per claim 7, directed to the method of claim 1, it is obvious for reasons set forth for claim 1, and further because It would have required only ordinary knowledge in the art to administer DRI for at least 6 months to provide a longer-term treatment and durable effect for fibromyalgia.

As per claims 8 and 18, they are obvious for reasons set forth for claim 1, and further because Hirsh discloses that milnacipran could provide relief from pain (para [0017]) and that in one of the early clinical trials, milnacipran dosage of 200 mg/day was superior to the lower doses (para [0010]) and that the incidence of certain adverse events increases with dosage, including nausea, vomiting, sweating, hot flashes, palpitations, tremor, anxiety, dysuria, and insomnia (para [0008]). It would have been obvious for a person having ordinary skills in the art to administer about 200 mg per day of milnacipran for the treatment of acute pain so as to get better therapeutic effect and then decrease the dose of milnacipran to about 100 mg per day when the acute pain has been treated to decrease the incidence of certain adverse events and administer about 100 mg per day of milnacipran to the patient for at least three months for the long-term treatment of fibromyalgia and its symptoms.

As per claim 9, directed to the method of claim 1, it is obvious for reasons set forth for claim 1, and further because Hirsh discloses that milnacipran can be administered adjunctively with other active compounds such as analgesics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, sedatives, hypnotics, antipsychotics, bronchodilators, anti asthma drugs, cardiovascular drugs, corticosteroids, dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants, nutritional agents, vitamins, parasympathomimetics, stimulants, anorectics and anti-narcoleptics (para [0006]).

As per claim 10, directed to the method of claim 9, it is obvious for reasons set forth for claim 9, and further because Hirsh discloses that "specific examples of compounds that can be adjunctively administered with milnacipran include, but are not limited to, amphetamine, caffeine, clonidine, codeine, modafinil, morphine, gabapentin, propranolol, pregabalin, pramipexole, sibutramine, tizanidine, tramadol, and isomers, salts, and combinations thereof." (para [0007])

As per claim 11, it is obvious for reasons set forth for claims 1 and 8, and further because it would have been obvious for a person having ordinary skills in the art to administer a dual re-uptake inhibitor (DRI) to the patient for at least three months to provide long-term treatment of a pain symptom associated with fibromyalgia syndrome in a patient.

As per claims 12, 13, 14, 15, 16, 17, they are obvious for reasons set forth for claim 11, and, individually for claims 2, 3, 4, 5, 6, 7, respectively.

--Please See Continuation Sheet--

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US06/37714

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

Claims 12-18 are objected to because they are identical to claims 2-8, respectively.

Claim 12 was searched as being dependent on claim 11 instead of claim 1;

Claim 13 was searched as being dependent on claim 12 instead of claim 2;

Claim 14 was searched as being dependent on claim 13 instead of claim 3;

Claims 15 and 16 were searched as being dependent on claim 14 instead of claim 4;

Claim 17 was searched as being dependent on claim 11 instead of claim 1.

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US06/37714

76

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of:

As per claim 19, directed to the method of claim 11, comprising adjunctively administering a second active compound, wherein the second active compound is selected from the group consisting of an antidepressant, an analgesic, a muscle relaxant, an anorectic, a stimulant, an antiepileptic drug, a beta blocker, a sedative, a hypnotic and combinations thereof, Hirsh discloses that "mirtazapine can be administered adjunctively with other active compounds such as analgesics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, sedatives, hypnotics, antipsychotics, bronchodilators, anti asthma drugs, cardiovascular drugs, corticosteroids, dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants, nutritional agents, vitamins, parasympathomimetics, stimulants, anorectics and anti-narcoleptics." (para (0088))

As per claim 20, directed to the method of claim 19, wherein the second active compound is selected from the group consisting of modafinil, XR13512, gabapentin, pregabalin, pramipexole, 1DOPA, amphetamine, lizanidine, clonidine, tramadol, morphine, tricyclic antidepressants, codeine, carbamazepine, sibutramine, valium, trazodone, caffeine, nicergoline, bifemelane, propranolol, atenolol and combinations thereof, Hirsh discloses that "[s]pecific examples of compounds that can be adjunctively administered with mirtazapine include, but are not limited to, amphetamine, caffeine, clonidine, codeine, modafinil, morphine, gabapentin, propranolol, pregabalin, pramipexole, sibutramine, lizanidine, tramadol and isomers, salts, and combinations thereof." (para (0087))

Claims 1-20 have industrial applicability as defined by PCT Article 33(4) because the subject matter can be made or used in industry.

77

APOSTILLE*(Convention de La Haye du 5 octobre 1961)*

1. Country: United States of America

This public document

2. has been signed by W. Montgomery

3. acting in the capacity of Certifying Officer

4. bears the seal/stamp of U.S. Patent and Trademark Office

Certified

5. at Washington, D.C.

6. the thirteenth of May, 2008

7. by ~~Assistant~~ *Authentication Officer, United States Department of State*

8. No. 08022604-8

9. Seal/Stamp:

10. Signature:



Denitra T. Hawkins

A
78



A 7125574

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

May 02, 2008

THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
APRIL 22, 2008.

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office



W. Montgomery
W. MONTGOMERY
Certifying Officer

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

04/22/2008
 500519978

XZ
 74

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Srinivas G. Rao	04/11/2008
Michael R. Gendreau	04/14/2008
Jay D. Kranzler	04/11/2008

RECEIVING PARTY DATA

Name:	Cypress Bioscience, Inc.
Street Address:	4350 Executive Drive, Suite 325
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121

PROPERTY NUMBERS Total: 1

Property Type	Number
PCT Number:	US0637714

CORRESPONDENCE DATA

Fax Number: (212)527-7701
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: (212) 527-7700
 Email: kharihar@darbylaw.com

Correspondent Name: S. Peter Ludwig
 Address Line 1: P.O. Box 770
 Address Line 2: Church Street Station
 Address Line 4: New York, NEW YORK 10008-0770

ATTORNEY DOCKET NUMBER:	20268/2203444-WO0
NAME OF SUBMITTER:	Katherine Harihar

Total Attachments: 3
 source=01503231#page1.ttf

OP \$40.00 US0637714

REEL 020838 FRAME 0870

125
81

Attorney Docket No.: 20268/2203444-W00

ASSIGNMENT

I, Srinivas G. Rao, a citizen of the United States of America, residing at 4350 Executive Drive, Suite 325; San Diego, California 92121; UNITED STATES OF AMERICA; and

I, Michael R. Gendreau, a citizen of the United States of America, residing at 12730 Shadowline Street; Poway, California 92064; UNITED STATES OF AMERICA; and

I, Jay D. Kranzler, a citizen of the United States of America, residing at 7935 Via Capri; La Jolla, California 92037; UNITED STATES OF AMERICA;

and each of us, if more than one person is identified above (hereinafter "ASSIGNOR") in consideration of the sum of Ten Dollars (\$10.00), or the equivalent thereof, and other good and valuable consideration, the sufficiency of which and receipt of which are hereby acknowledged, paid to ASSIGNOR by

Cypress Bioscience, Inc.

a Corporation organized under the laws of Delaware, located at 4350 Executive Drive, Suite 325, San Diego, California 92121 (hereinafter "ASSIGNEE"), do hereby sell and assign to said ASSIGNEE, its successors and assigns, the below indicated right, title, and interest, throughout the world in and to my Invention entitled:

**MILNACIPRAN FOR THE LONG-TERM TREATMENT OF FIBROMYALGIA
SYNDROME**

invented by me and described in and Provisional Patent Application No. 60/721,722, filed on September 28, 2005, in the United States of America and International Patent Application Serial No. PCT/US06/37714 filed September 27, 2006 and all patents, divisions, reissues, continuations and any extensions thereof and rights of priority therein, said interest being my entire ownership interest in the same, to be held and enjoyed by said ASSIGNEE, its successors, assigns, or other legal representatives, to the full end of the term thereof, as fully and entirely as the same would have been held and enjoyed by me if this assignment and sale had not been made, including all rights of Assignor to recover for past infringement thereof;

16
89

Attorney Docket No.: 20268/2203444-WO0


And for the consideration aforesaid, I hereby covenant and agree to and with said ASSIGNEE, its successors and assigns, that whenever ASSIGNEE, its counsel or representative, or the counsel or representative of its successors or assigns, shall advise that an amendment to, or a division of, or any other proceeding or action in connection with an application concerning said Invention, including interference proceedings, is lawful and desirable, or that a reissue or continuation or extension of such application or patent issuing therefrom is lawful and desirable, I will sign all papers and drawings, take all rightful oaths and affidavits, and do all acts necessary or required to be done for the procurement of all lawful rights associated with the Invention, or for the reissue or continuation or extension of the same, will do all acts necessary or required to secure in said ASSIGNEE, its successors or assigns, the title to and full benefit of all rights hereby assigned, without charge to said ASSIGNEE or its successors or assigns, but at its or their expense; and I hereby appoint every present or future officer of said ASSIGNEE as my agent to sign all such papers and to do all such necessary acts on my behalf, to the fullest extent permitted by law;

And I hereby authorize and request the Commission of Patents and Trademarks and any other granting authority to issue any Letters Patent resulting from said Invention and application(s) concerning same to said ASSIGNEE.


This assignment shall have an effective date corresponding to the last date of execution.

I declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that I have signed this document as my own free act and that all of the foregoing is true and correct.


Dated: April 11, 2008


Srinivas G. Rao, Inventor

Dated: April 14, 2008


Michael R. Gendreau, Inventor

Dated: April 11, 2008


Jay D. Krankler, Inventor

ACCEPTANCE BY ASSIGNEE

In connection with an assignment in any jurisdiction in which an acceptance by ASSIGNEE is required, I hereby accept this assignment on behalf of Cypress Bioscience, Inc.. I declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that (check all that apply):

- ☒ I am an officer of the above-identified ASSIGNEE,
- ☐ I have signed this document on behalf of ASSIGNEE with the full authority of its board of directors,

and that all the foregoing is true and correct.

Dated:

April 14, 2008

By:

Name:

Title:

Denise Wheeler

Denise Wheeler

General Counsel

49
83

TRADUCCIÓN AL ESPAÑOL del documento de cesión de solicitud de patente a
CYPRESS BIOSCIENCE, INC., firmado por los cedentes y el cesionario.

APOSTILLA

(CONVENCIÓN DE LA HAYA DEL 5 DE JULIO DE 1961)

1. PAÍS: ESTADOS UNIDOS DE AMERICA
2. ESTE DOCUMENTO PÚBLICO HA SIDO FIRMADO POR:
W. MONTGOMERY
3. ACTUANDO EN CAPACIDAD DE: FUNCIONARIO QUE CERTIFICA
4. LLEVA EL SELLO/TIMBRE DE: OFICINA DE MARCAS Y PATENTES DE
ESTADOS UNIDOS

CERTIFICADO

5. EN WASHINGTON, D. C.
6. EL TRECE MAYO DE 2008
7. POR FUNCIONARIO DE AUTENTICACIONES, DEPARTAMENTO DE
ESTADO DE ESTADOS UNIDOS
8. NO. 08022604-8
9. SELLO/TIMBRE
10. FIRMA

(FIRMA)

DENITRA T. HAWKINS

LOS ESTADOS UNIDOS DE AMÉRICA
A TODO AQUEL AL QUE PUEDA LLEGARLE LA PRESENTE:

DEPARTAMENTO DE COMERCIO DE ESTADOS UNIDOS
Oficina de Marcas y Patentes de Estados Unidos

Mayo 2 de 2008

ESTE ES PARA CERTIFICAR QUE EL ANEXO ES UNA COPIA VERDADERA DE
LOS ARCHIVOS DE ESTA OFICINA DE UN DOCUMENTO REGISTRADO EL 22
DE ABRIL DE 2008.

Por autoridad del
Subsecretario de Comercio para la Propiedad Intelectual
y Director de la Oficina de Marcas y Patentes de los Estados Unidos

Hay un sello que dice:

[Oficina de Marcas y
Patentes de Estados Unidos
Departamento de Comercio]

(firma)
W. MONTGOMERY
Funcionario que Certifica

CESIÓN DE PATENTE

Versión electrónica v1.1
Versión en papel v1.1

22/04/2008
500519978

TIPO DE SUMISIÓN: NUEVA CESIÓN

NATURALEZA DEL ASUNTO: CESIÓN

DATOS DE LA PARTE CONVERGENTE

Nombre	Fecha de ejecución
Srinivas G. Rao	11/04/2008
Michael R. Gendreau	14/04/2008
Jay D. Kranzler	11/04/2008

DATOS DE LA PARTE QUE RECIBE

Nombre: Cypress Bioscience, Inc.
Dirección de la calle: 4350 Executive Drive, Suite 325
Ciudad: San Diego
Estado/País: California
Código Postal: 92121

Total de NÚMERO DE PROPIETARIOS: 1

Tipo de propiedad	Número
Número de PCT	US0637714

DATOS DE CORRESPONDENCIA

Número de fax: (212) 527-7701
La correspondencia será enviada vía Correo de EE. UU. Cuando el intento por fax no sea exitoso.

Teléfono: (212) 527-7700
Correo electrónico: cariar@darbylaw.com
Nombre de correspondencia: S. Peter Ludwig
Dirección línea 1: P. O. Box 770
Dirección línea 2: Church Street Station
Dirección línea 4: New York, NEW YORK 10008-0770

NÚMERO DE LISTA DEL ABOGADO: 20268/2203444-WO0

NOMBRE DEL APORTANTE: Katherine Harihar

Anexos totales: 3
Fuente=01503231#página 1.tif

CESIÓN

Yo, Srinivas G. Rao, ciudadano de los estados Unidos de América, residente en 4350 Executive Drive, Suite 325; San Diego, California 92121; ESTADOS UNIDOS DE AMÉRICA; y

Yo, Michael R. Gendreau, ciudadano de los estados unidos de América, residente en 12730 Shadowline Street; Poway, California 92064; ESTADOS UNIDOS DE AMÉRICA; y

Yo, Jay D. Kranzler, ciudadano de los Estados Unidos de América, residente en 7935 Via Capri; la Jolla, California 92037; ESTADOS UNIDOS DE AMÉRICA;

Y cada uno de nosotros, si más de una persona se identifica arriba (en adelante "CEDENTE") en contraprestación de la suma de Diez Dólares (US \$10), o su equivalente, y otras buenas y valiosas contraprestaciones, la suficiencia de las cuales y el recibo de las cuales están aquí declaradas, pagadas al CEDENTE por

Cypress Bioscience, Inc.

Una corporación organizada según las leyes de Delaware, localizada en 4350 Executive Drive, Suite 325, San Diego, California 92121 (en adelante "CESIONARIO"), vendo y cedo a dicho CESIONARIO, sus sucesores y asignatarios, el derecho indicado abajo, el título e interés, **alrededor del mundo** en y para mi invención titulada:

MILNACIPRAN PARA EL TRATAMIENTO A LARGO PLAZO DEL SÍNDROME DE FIBROMIALGIA

Inventada por mí y descrita en y en la Solicitud Provisional de Patente No. 60/721,722, presentada en septiembre 28 de 2005, en los Estados Unidos de América y en el Serial de la Solicitud de Patente Internacional No. PCT/US06/37714 presentada el 27 de septiembre de 2006, y todas las patentes, divisiones, reexpediciones, continuaciones y cualquier extensión y derechos de prioridad, al ser dicho internes de mi total propiedad, para ser mantenido y disfrutado por dicho CESIONARIO, sus sucesores, asignatarios, u otros representantes legales, para la total finalización del término, como completa y enteramente habría sido mantenida y disfrutada por mí si esta cesión y venta no hubiera sido hecha, incluyendo todos los derechos del Cedente a reclamar por infracciones pasadas;

83
89

Y por la contraprestación predicha, yo acuerdo para y con dicho CESIONARIO, sus sucesores y asignatarios que cualquier CESIONARIO, su consejero o representante, o el consejero o representante de sus sucesores o asignatarios, informarán que una corrección a, o una división de, o cualquier otro procedimiento o acción en conexión con una solicitud relativa a dicha Invención, incluyendo los procedimientos de interferencia, es legal y deseable, yo firmaré todos los papeles y dibujos, tomaré todos los juramentos y declaraciones correctos, y haré todos los actos necesarios o requeridos para la obtención de todos los derechos asociados con la Invención, o por la reexpedición o continuación o extensión de los mismos, haré todos los actos necesarios o requeridos para asegurar en dicho CESIONARIO sus sucesores o asignatarios, el título y el beneficio completo de todos los derechos aquí asignados, sin cargo a dicho CESIONARIO o sus sucesores o asignatarios, sino a su costo; y designo a partir de aquí a todos los funcionarios presentes o futuros de dicho CESIONARIO como mi agente para firmar todos los papeles y hacer todos los actos necesarios en mi nombre, según lo permita la ley;

Y yo también autorizo y requiero a la Comisión de Patentes y Marcas y a cualquier otra autoridad que conceda patentes resultantes de dicha Invención y solicitud (es) referentes a dicho CESIONARIO.

Esta cesión tendrá una fecha efectiva correspondiente a la última fecha de ejecución.

Declaro bajo pena de falso testimonio según las leyes de los Estados Unidos de América, y bajo las penas de las leyes de cualquier otra jurisdicción ante la que este documento pueda ser presentado, que he firmado este documento como un acto libre y que todo lo precedente es verdadero y correcto.

Fechado: Abril 11 de 2008

(Firma)

Srinivas G. Rao, Inventor

Fechado: Abril 14 de 2008

(Firma)

Michael R. Gendreau, Inventor

Fechado: Abril 11 de 2008

(Firma)

Jay D. Kranzler, Inventor

ACEPTACIÓN DEL CESIONARIO

En conexión con una cesión en cualquier jurisdicción en la que una aceptación por el CESIONARIO se requiera, yo de esta forma acepto esta cesión en nombre de Cypress Bioscience, Inc. Declaro bajo pena de falso testimonio según las leyes de los Estados Unidos de América, y bajo las penas de las leyes de cualquier otra jurisdicción ante la que este documento pueda ser presentado, que (marcar todas a las que se aplica):

☒ Soy un funcionario del CESIONARIO arriba identificado

☐ Yo he firmado este documento en nombre del CESIONARIO con la total autoridad de su junta directiva,

Y que todo lo anterior es verdadero y correcto.

Fechado: Abril 14 de 2008

Por: (Firma)

Nombre: (Ilegible)

Cargo: Director General

State of California

SECRETARY OF STATE

For use in Colombia. All other use prohibited.



APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America
This public document
2. has been signed by M. Hammack
3. acting in the capacity of Notary Public, State of California
4. bears the seal/stamp of M. Hammack, Notary Public,
State of California

CERTIFIED

5. At Sacramento, California
6. the 7th day of May 2008
7. by Deputy Secretary of State, State of California
8. No. 532421
9. Seal/Stamp:



10. Signature

Jana Bowen
Secretary of State

BY *[Signature]*

Brigard & Castro

BOGOTA - COLOMBIA

PODER

Yo (nosotros), **CYPRESS BIOSCIENCE, INC.**

domiciliado(s) en, 4350 Executive Drive, Suite 325, San Diego, CA 92121, Estados Unidos de América

Nombro(amos) a: **JUAN PABLO CADENA SARMIENTO** y/o **CARLOS H. PALACIO EASTMAN** y/o **MARTIN E. TORRES CARDOZO**, de Bogotá, Colombia, apoderados verdaderos y legales con poder especial, amplio y suficiente, para recabar de las oficinas y autoridades colombianas administrativas, judiciales y de policía, en cualquier instancia o recurso, la obtención de patentes de invención, registros de marcas, diseños industriales, modelos de utilidad, depósitos de nombres comerciales, lemas comerciales y enseñas, registros de derechos de autor y contratos sobre los mismos, obtención de certificados de obtentor de variedades vegetales, así como sus prórrogas, renovaciones, anotaciones de traspaso, cambios de nombre, domicilio y/o dirección; elaborar, tramitar y registrar contratos de licencia y licencias de cualesquiera clases; intervenir como demandante o como demandado en cualquier instancia y recurso ante cualquier juez, corporación, funcionario público o autoridad en acciones judiciales, administrativas y de policía tales como: oposiciones al registro de marcas; acciones de caducidad, cancelación y nulidad; acciones reivindicatorias, acciones derivadas de la obtención o explotación de licencias; acciones de competencia desleal; demandas penales; acciones de indemnización de perjuicios, reclamos y observaciones a solicitudes de patentes, diseños industriales, modelos de utilidad, en el ejercicio de medidas cautelares y en otras acciones o medidas similares.

A este efecto, lo(s) faculto(amos) para elevar solicitudes, formular descripciones, enmiendas, protestas, declaraciones, oposiciones, cancelaciones, nulidades, apelaciones y reclamos; pagar impuestos, cuotas y gravámenes prescritos por la ley; renunciar o desistir a derechos concedidos o en curso de concesión; recibir toda clase de documentos y valores, dando el descargo respectivo, y, en general, para dar ante dichas autoridades todos los pasos necesarios al efecto indicado y tomar todas las medidas que creyeren conducentes al resguardo de mis (nuestros) intereses, con todas las demás facultades legales necesarias.

Este poder comprende la facultad de ratificar o confirmar en mi (nuestro) nombre lo actuado así como la facultad de desistir, transigir, comprometer, y la de sustituirlo en todo o en parte y revocar sustituciones. Asimismo nombro(amos) a: **JUAN PABLO CADENA SARMIENTO** y/o **CARLOS H. PALACIO EASTMAN** y/o **MARTIN E. TORRES CARDOZO**, domiciliado(s) en la Carrera 7 No. 71-21, Torre B, Piso 4, mis (nuestros) apoderados en Colombia, con facultades para recibir notificaciones y designar apoderados judiciales o extrajudiciales.

Otorgado y firmado en _____

hoy de de 2008

Firma

Nombre
Cargo

POWER OF ATTORNEY

I (We), **CYPRESS BIOSCIENCE, INC.**

domiciled in, 4350 Executive Drive, Suite 325, San Diego, CA 92121, United States of America

Hereby appoints **JUAN PABLO CADENA SARMIENTO** and/or **CARLOS H. PALACIO EASTMAN** and/or **MARTIN E. TORRES CARDOZO**, of Bogotá, Colombia, my (our) true and lawful attorneys with special, ample and sufficient power to obtain from the Colombian administrative, judicial and police offices and authorities, in any instance, privileges of patents of invention, registration of trademarks, industrial designs and utility models; registration of commercial names, slogans and emblems, registration of copyright and contracts related thereto; certificates of obtainers of vegetable varieties, as well as extensions, renewals and recordal of assignments and changes of name, domicile and/or address related to the above; to prepare, prosecute and register licenses of any kind; to act as plaintiff or defendant in any instance or recourse, and before any judge, corporation, public official or authority in judicial, administrative and police actions, such as: oppositions to the registration of trademarks, cancellation and nullity actions; claim actions derived from the obtaining or exploitation of licenses, action of unfair competition; criminal proceedings, actions for payment of damages; claims or observations on patents, applications, models, industrial designs, and utility models and the exercise of preventive measures and in other actions or similar proceedings.

To that effect, I hereby empower to file applications, formulate descriptions, amendments, protests, declarations, oppositions, cancellations, nullities, appeals and claims; to pay taxes, quotas and assessments prescribed by law, renounce or waive the rights granted or in the process of granting; to receive all kinds of documents and valuables, giving the respective release of receipt, and, in general, to take before said authorities the necessary steps to such effect, and any measures that they may deem pertinent to the safeguard of my (our) interest(s) with all the other necessary legal powers.

This power includes the faculty to ratify or confirm desist, settle and compromise on my (our) behalf, and to substitute this power in whole or in part and to revoke substitutions. At the same time I (We) hereby appoint **JUAN PABLO CADENA SARMIENTO** and/or **CARLOS H. PALACIO EASTMAN** and/or **MARTIN E. TORRES CARDOZO**, domiciled in Carrera 7 No. 71-21, Torre B, Piso 4, my (our) attorney(s) in fact, with powers to receive notifications and to designate judicial and extrajudicial attorneys.

Granted and signed in SAN DIEGO, CA

this 29 day of APRIL 2008

Signature

Name SEBINAS RAO

Title CHIEF SCIENTIFIC OFFICER

CERTIFICADO NOTARIAL (SOCIEDAD)

NOTARIAL CERTIFICATE (CORPORATION)

Hoy de de personalmente compareció ante mí

On this day of of personally appeared before me

a quien conozco, y de quien me consta que firmó el anterior documento, debidamente juramentado declaró y dijo que él (ella) es

to me known, and known to me to be the person who signed the foregoing instrument who being by me duly sworn did depose and say that he (she) is the

de, CYPRESS BIOSCIENCE, INC.

of, CYPRESS BIOSCIENCE, INC.

Sociedad legalmente constituida para un periodo de duración que aún no ha terminado; que el declarante está autorizado por dicha compañía para conferir este poder; que el sello estampado por él al pie de tal poder, en nombre y representación de la expresada compañía, es el sello oficial de ella; y que el objeto para el cual se confiere este instrumento está comprendido dentro del objeto social de la sociedad.

Which is legally constituted for a term not yet expired, that deponent is authorized by said Company to confer this Power of Attorney: that the seal affixed hereunto by the deponent in the name and on behalf of said Corporation is the corporate seal thereof; and that the purpose for which this instrument is granted is included within the corporate purpose of company.

El suscrito Notario hace constar que tuvo a la vista las pruebas de la existencia de la sociedad.

The undersigned Notary Public attests that he has seen the documents that prove the existence of the company.

Estado de con fecha

State of under date of


y que quien confiere el presente poder es su representante.

and that he (she) who grants the present power of attorney is its Representative.

Notario Público (sello)

Public Notary (Seal)

CERTIFICADO NOTARIAL
PERSONA NATURAL



NOTARIAL CERTIFICATE
NATURAL PERSON

Hoy de de , compareció(eron) ante mí

On this day of of personally appeared before me

a quien (es) conozco y me consta que es(son) la(s) persona(s) firmante(s) del documento que precede y quien(es) declara(n) que otorgan el mismo para los fines y propósitos que en él se expresan.

who is(are) known to me and who I attest executed the foregoing document and he (they) declared he (they) grant(s) the document for the uses and purposes therein expressed.

Notario Público (sello)

Notary Public (Seal)

LEGALIZACIÓN POR APOSTILLA ES REQUERIDA.

LEGALIZATION BY APOSTILLE IS REQUIRED.

28
94

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of San Diego

On April 29, 2008

before me,


M. Hammack

Here Insert Name and Title of the Officer

personally appeared

Srinivas G. Rao

Name(s) of Signer(s)



who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature

M. Hammack

Signature of Notary Public

Place Notary Seal Above

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: Power of Attorney - Colombia

Document Date: N/A

Number of Pages: + this page

Signer(s) Other Than Named Above: N/A

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

- ☐ Individual
☒ Corporate Officer — Title(s): CSO
☐ Partner — ☐ Limited ☐ General
☐ Attorney in Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other: _____

Signer Is Representing: _____


Cypress Bioscience, Inc.

RIGHT THUMBPRINT OF SIGNER
Top of thumb here

Signer's Name: _____

- ☐ Individual
☐ Corporate Officer — Title(s): CSO, D.C., Colombia
☐ Partner — ☐ Limited ☐ General
☐ Attorney in Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other: _____

Signer Is Representing: _____



RIGHT THUMBPRINT OF SIGNER
Top of thumb here


Apostille

(Convention de La Haye du 5 Octobre 1961)

1. Country: United States of America
2. This public document:
has been signed by Harriet Smith Windsor
3. acting in the capacity of Secretary of State of Delaware
4. bears the seal/stamp of Office of Secretary of State


Certified

5. at Dover, Delaware
6. the twenty-seventh day of May, A.D. 2008
7. by Secretary of State, Delaware Department of State
8. No. 0353261
9. Seal/Stamp:



10. Signature:

Harriet Smith Windsor
Secretary of State




Delaware

PAGE 1

The First State


I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY "CYPRESS BIOSCIENCE, INC." IS DULY INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE AND IS IN GOOD STANDING AND HAS A LEGAL CORPORATE EXISTENCE SO FAR AS THE RECORDS OF THIS OFFICE SHOW, AS OF THE TWENTY-SEVENTH DAY OF MAY, A.D. 2008.



0924824

080601649

You may verify this certificate
at corp.delaware.gov/authver.



Harriet Smith Windsor

Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 6614970

DATE: 05-27-08

37
97

TRADUCCIÓN AL ESPAÑOL del documento de PODER otorgado por
CYPRESS BIOSCIENCE, INC., con domicilio en 4350 Executive Drive, Suite
325, San diego, CA 92121, Estados Unidos de América

Estado de California
SECRETARÍA DE ESTADO

Para uso en Colombia. Cualquier otro uso está prohibido.

APOSTILLA

(Convención de La Haya del 5 de octubre de 1961)


1. País: Estados Unidos de América

Este documento público

2. Ha sido firmado por M. Hammack

3. Actuando en capacidad de Notario Público, Estado de California

4. lleva el sello/timbre de M. Hammack, Notario Público
Estado de California



Certificado

5. En Sacramento, California

6. el 7 de mayo de 2008

7. por el Secretario de Estado Delegado, Estado de California

8. No. 532421

9. Sello/Timbre

10. Firma:

Hay un sello que dice:

EL GRAN SELLO DELE STADO DE CALIFORNIA

(firma)
Secretario de Estado
Por (Firma ilegible)

32
98

CALIFORNIA DECLARACIÓN PARA TODO PROPÓSITO

Estado de California

Condado de San Diego]

El 29 de abril de 2008 ante mí, M. Hammack

Fecha

Inserte aquí el nombre y cargo del funcionario

Personalmente compareció Srinivas G. Rao
Nombre del firmante

Hay un sello que dice:


M. HAMMACK
de Comisión 1556695
Notario Público – California
Condado de San Diego
Mi comisión vence el 4 de marzo de 2009

Quien demostró ante mí, sobre las bases de evidencia satisfactoria, ser la persona cuyo nombre está suscrito dentro del instrumento y declaró ante mí que ejecutó el mismo en su capacidad autorizada, y que por su firma en el instrumento la persona o la entidad en nombre de la cual actuó ejecutó el instrumento.

Yo certifico que, bajo pena de FALSO TESTIMONIO bajo las leyes del Estado de California que el párrafo precedente es verdadero y correcto.

EN TESTIMONIO DE LO CUAL, mi firma y sello oficial

Firma (Firma)
Firma del notario público



OPCIONAL

Aunque la información de abajo no es requerida legalmente, puede resultar valiosa para las personas que se apoyan en el documento y podrían prevenir remoción fraudulenta y reanexo de esta forma a otro documento.

Descripción del documento anexo

Título o tipo de documento: Poder - Colombia

Fecha del Documento: N/A Número de páginas: 2 + esta página

Firmantes diferentes al nombrado arriba: N/A

Calidad(es) reclamada(s) por el firmante(s)

Nombre del firmante: _____

☐ Individuo

☒ Funcionario corporativo

Socio - ☐ Limitado ☐ General

☐ Abogado de hecho

☐ Fideicomisario

☐ Tutor o curador

☐ Otro

El firmante está representando a: _____

Cypress Bioscience, INC.

33
99

APOSTILLA

(Convención de La Haya del 5 de octubre de 1961)

- 1. País: Estados Unidos de América
Este documento público
- 2. Ha sido firmado por Harriet Smith Windsor
- 3. Actuando en capacidad de Secretario de estado del Estado de Delaware
- 4. lleva el sello/timbre de La oficina del Secretario de Estado

Certificado

- 5. En Dover, Delaware
- 6. el 27 de mayo de 2008
- 7. por el Secretario de Estado, Departamento de Estado de Delaware
- 8. No. 0353261
- 9. Sello/Timbre
- 10. Firma:

Hay un sello que dice:

OFICINA DEL SECRETARIO
1798 DELAWARE 1855

(firma)

En la Notaría Cuarenta de este Circuito se
deja la presente fotocopia que coincide con
el original que se ha tenido a la vista.

12 AGO. 2008


NOTARIO CUARENTA
Dover, DE
Agustín P. Lleras

Secretario de Estado

Delaware

El Primer Estado

YO, HARRIET SMITH WINDSOR, SECRETARIO DE ESTADO DEL ESTADO DE DELAWARE, CERTIFICO QUE "CYPRESS BIOSCIENCE, INC." ESTÁ DEBIDAMENTE INCORPORADA SEGÚN LAS LEYES DEL ESTADO DE DELAWARE Y TIENE BUENA POSICIÓN Y TIENE UNA EXISTENCIA LEGAL CORPORATIVA SEGÚN LO MUESTRAN LOS ARCHIVOS DE ESTA OFICINA, A 29 DE MAYO DE 2008.



0924824

Hay un sello que dice:

(Firma)

0806016

OFICINA DEL SECRETARIO
1798 DELAWARE 1855

Harriet Smith Windsor, Secretario de Estado
AUTENTICACIÓN: 6614970

FECHA: 27- MAYO - 2008

REPUBLICA DE COLOMBIA
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Folio 101

2020
Bogotá D.C.,


Doctor(a)
CADENA SARMIENTO JUAN PABLO
Apoderado(a) y/o Representante de
CIPRESS BIOSCIENCE INC

REFERENCIA	Radicación No.	8 39648
	Solicitud internacional	PCT/US2006/037714
	Fecha inicio fase nacional	28/04/2008
	Trámite	11
	Evento	378
	Actuación	416
	Oficio No.	7893
	Folios	1

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en la Decisión 486 de la Comisión de la Comunidad Andina, el Tratado de Cooperación en Materia de Patentes (PCT), el Reglamento y la Circular Única de la Superintendencia de Industria y Comercio, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial.

Cúmplase
Dado en Bogotá DC

18 MAR. 2009


DORIS ELENA POLO CORDOBA
Jefe de la división de Nuevas Creaciones (E)

adpall

DIVISIÓN DE NUEVAS CREACIONES

RADICACIÓN EXPEDIENTE No.08-039648

EL EXTRACTO DE LA PRESENTE SOLICITUD DE **PATENTE DE INVENCION**

FUE PUBLICADO EN LA GACETA DE PROPIEDAD INDUSTRIAL No **604** DE

FECHA **29 DE MAYO DE 2009** EL TÉRMINO HÁBIL SEÑALADO POR LA LEY

EXPIRA EL **31 DE AGOSTO DEL 2009**

NOTA: Dentro del plazo de los seis (6) meses siguientes a partir de la fecha de publicación en la gaceta de Propiedad Industrial, deberá solicitar y cancelar el examen de patentabilidad so pena de que la solicitud caiga en abandono, de acuerdo con lo establecido en el Artículo 44 de la Decisión 486/2000.

SE PRESENTARON OPOSICIONES POR PARTE DE TERCEROS.

SI ☒ X ☐

NO ☐